Study design and Methodology

• In a double blind and randomized manner, 23 females supplemented their diet with ForsLean® (250 mg, n=7) or a placebo (n=12) two times per day for 12 weeks.
  
  
• Body composition (DEXA), body weight, and psychometric instruments were obtained at 0, 4, 8 & 12 weeks of supplementation.
  
  
• Fasting blood samples and dietary records (4-d) were obtained at 0 and 12 weeks. Side effects were recorded on a weekly basis.
  
  
  

Study results

Efficacy:

• No significant differences were observed in caloric or macronutrient intake.
  
  
• ForsLean® tended to mitigate gains in body mass (-0.7±1.8,1.0±2.5 kg, p=0.10) and scanned mass (-0.2±1.3, 1.7±2.9 kg, p=0.08) with no significant differences in fat mass (-0.2±0.7, 1.1±2.3 kg, p=0.16), fat free mass (-0.1±1.3, 0.6±1.2 kg, p=0.21), or body fat (-0.2±1.0, 0.4±1.4 %, p=0.40).
  
  
• Subjects in the ForsLean® group tended to report less fatigue (p=0.07), hunger (p=0.02), and fullness (p=0.04).

Safety:
No clinically significant interactions were seen in metabolic markers, blood lipids, muscle and liver enzymes, electrolytes, red cells, white cells, hormones (insulin, TSH, T3, and T4) , heart rate, blood pressure, or weekly reports of side effects.

Conclusion:

Results suggest that ForsLean® may help mitigate weight gain in overweight females with apparently no clinically significant side effects